Potential new marker for outcomes in Hodgkin lymphoma
Published on: 20 November 2019A protein called sIL-2R might help predict outcomes in people with classical Hodgkin lymphoma.
Researchers in Japan have identified a protein that might help predict who will respond well to treatment for classical Hodgkin lymphoma, and who might need more intensive treatment.
The protein is called ‘soluble interleukin-2 receptor’ or sIL-2R. It is made by lymphocytes and other immune cells and can be measured using a blood test.
The study found that people who had a high level of sIL-2R in their blood when they were diagnosed with classical Hodgkin lymphoma responded less well to ABVD treatment than people with lower levels of sIL-2R.
This was a very small study and more research is needed into the role of sIL-2R. If the results of this study are confirmed, measuring sIL-2R at diagnosis might help specialists identify people who need more intensive treatment strategies for classical Hodgkin lymphoma.
Find out more about classical Hodgkin lymphoma, or visit Lymphoma TrialsLink to find out about the latest research in lymphoma.
20 November 2019